ACS, Atrial Fibrillation, CHD, and CHF

- Total first-year costs of acute coronary syndrome in a managed care setting. 2005;11(4):300-06.

Adherence, Compliance, and Persistence

- Comparing medication persistence across 6 chronic therapy classes to identify the greatest need for improvement. 2009;15(9):728-40.
- Relationship of the magnitude of member cost-share and medication persistence with newly initiated renin angiotensin system blockers. 2007;13(8):664-76.
- Patient adherence with HMG reductase inhibitor therapy among users of two types of prescription services. 2002;8(3):186-91.
- Adherence, compliance, and persistence in drug therapy. 2002;8(3):177-78.
- Evaluating medication adherence: which measure is right for your program? 2000;6(6):499-504.

Adverse Drug Events

- Medical errors, adverse medical events, and PDRM. 2002;8(5):400.
- Evaluation of resources used to treat adverse events of selective serotonin reuptake inhibitor use. 2001;7(5):402-06.
Airway Disease and Allergic Rhinitis

- Quality of drug treatment of childhood persistent asthma in Maryland Medicaid recipients in transition from managed fee for service to managed capitation. 2007;13(4):310-18.
- Health care utilization determined from administrative claims analysis for patients who received inhaled corticosteroids with either montelukast or salmeterol. [letter] 2006;12(6):486-87.
- Administrative claims analysis of asthma-related health care utilization for patients who received inhaled corticosteroids with either montelukast or salmeterol as combination therapy. 2006;12(4):310-21.
- Selectivity and specificity are the keys to cost-effective use of omalizumab for allergic asthma. [editorial] 2005;11(9):774-76.
- Evaluation of omalizumab from a health care perspective. 2005;11(9):733-45.
- Evaluating asthma medication use before and after an acute asthma-related event. 2001;7(4):303-08.

ALS (Amyotrophic Lateral Sclerosis)

Alzheimer’s Disease
- Cholinesterase inhibitor utilization patterns: just because it can be counted does not mean it counts. [commentary] 2008;14(5):462-64.

Arthritis and Joint Pain
- Review of eight pharmacoeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis. 2006;12(7):559-69.
• COX-2 inhibitors; little or no GI protection, increased risk of cardiovascular events, high cost, and other class-less effects. [editorial] 2005;11(7):590-93.

• Gastrointestinal bleeding rates among managed care patients newly started on COX-2 inhibitors or nonselective NSAIDs. 2005;11(7):550-58.


• Relationship of clinical factors to the use of COX-2 selective NSAIDs within an arthritis population in a large HMO. 2002;8(4):252-58.

• Economic considerations in the management of arthritis. 1999;5(6):476-78, 481-82, 484.


**Atopic Dermatitis**

• Atopic march to a dead end or does the theory really have legs? [editorial] 2007;13(9):810-11.

• Economic burden of atopic manifestations in patients with atopic dermatitis—analysis of administrative claims. 2007;13(9):778-89.

• Administrative claims analysis of utilization and costs of care in health plan members with atopic dermatitis who had prior use of a topical corticosteroid and who initiate therapy with pimecrolimus or tacrolimus. 2007;13(4):349-59.


• The effect of atopic dermatitis on total burden of illness and quality of life on adults and children in a large managed care organization. 2002;8(5):333-42.

**Attention-Deficit/Hyperactivity Disorder (ADHD)**

• Changes and challenges: managing ADHD in a fast-paced world. [supplement] 2007;13(9, S-b):S1-S16.

• ADD or ADHD or what exactly?—GIGO part II and other lessons in research with administrative claims. [editorial] 2007;13(7):617-19.

• Continuity in methylphenidate treatment of adults with attention-deficit/hyperactivity disorder. 2007;13(7):570-77.

• Health care costs of adults treated for attention-deficit/hyperactivity disorder who received alternative drug therapies. 2007;13(7):561-69.


• Physician perceptions of the use of medications for attention deficit hyperactivity disorder. 2003;9(5):416-23.

**Behavioral Health**


**Benign Prostatic Hyperplasia**


**Biotechnology**


**Cancer and Chemotherapy**

• Payer costs for inpatient treatment of pathologic fracture, surgery to bone, and spinal cord compression among patients with multiple myeloma or bone metastasis secondary to prostate or breast cancer. 2010;16(9):693-702.

• Budgetary impact of treatment with adjuvant imatinib for 1 year following surgical resection of kit-positive localized gastrointestinal stromal tumors. 2010;16(7):482-91.


• Budget impact analysis of ixabepilone use according to FDA-approved labeling in treatment-resistant metastatic breast cancer. 2009;15(6):467-75.

• Use of erythropoiesis-stimulating agents among chemotherapy patients with hemoglobin exceeding 12 grams per deciliter. 2008;14(9):858-69.


• Recent advances in the understanding and treatment of multiple myeloma. [supplement] 2008;14(7-S):S1-S29.


• Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3-4 week chemotherapy regimens in community oncology practices. 2007;13(4):337-48.

• Pharmacy benefit spending on oral chemotherapy drugs. 2006;12(7):570-77.


**Capitation and Risk-Financing Methods**


• Contractual arrangements between HMOs and medical groups to manage drug costs. [editorial] 2003;9(6):572.


• Managing pharmacy risk in physician groups. 1999;5(5):382-84.
Chronic Kidney Disease (CKD)

- Clinical and economic outcomes in Medicare beneficiaries with stage 3 or stage 4 kidney disease and anemia: the role of intravenous iron therapy. 2010;16(8):605-15.
- Assessment of time and practice resources required to provide weekly or monthly erythropoiesis-stimulating protein therapy to chronic kidney disease patients in the physician office setting. 2006;12(9):714-25.

Clinical Pharmacy—Patient Consultation


Clinical Pharmacy—Payment for Services and Medication Therapy Management

- Outcomes of a rheumatoid arthritis disease therapy management program focusing on medication adherence. 2010;16(8):593-604.
- Medication therapy management: 10 years of experience in a large integrated health care system. 2010;16(3):185-95.
- PSTAC survey in 2006 was instrumental in obtaining permanent (category 1) CPT codes for MTM services performed by pharmacists. [letter] 2008;14(1):86-87.
- Results from a mailed promotion of medication reviews among Department of Defense beneficiaries receiving 10 or more chronic medications. 2010;16(8):578-92.
- Descriptive analysis of a clinical pharmacy intervention to improve the appropriate use of stress ulcer prophylaxis in a hospital infectious disease ward. 2010;16(2):114-21.
- Adherence to clinical practice guidelines for 7 chronic conditions in long-term-care patients who received pharmacist disease management services versus traditional drug regimen review. 2007;13(1):28-36.
- Experience with a clinical decision support system in community pharmacies to recommend narrow-spectrum antimicrobials, nonantimicrobial prescriptions, and OTC products to decrease broad-spectrum antimicrobial use. 2006;12(5):390-97.
- Assessment of patient satisfaction with telephone and mail interventions provided by a clinical pharmacy cardiac risk reduction service. 2005;11(5):403-09.
Clinical Practice Guidelines (CPGs), Evidence-Based Practice and Quality Improvement

- Development and delivery of a quality improvement program to reduce antipsychotic polytherapy. 2010;16(6):393-401.
- Intervention to increase the proportion of acute myocardial infarction or coronary artery bypass graft patients receiving an order for aspirin at hospital discharge. 2010;16(5):329-36.
- Call for letters regarding disclosure of potential conflicts of interest in the managed care literature—Too much, too little, or just about right? [editorial] 2009;15(2):166.
- Rethinking the “whodunnit” approach to assessing the quality of health care research—a call to focus on the evidence in evidence-based practice. [editorial] 2008;14(7):661-74.
- Liver and thyroid monitoring in ambulatory patients prescribed amiodarone in 10 HMOs. 2006;12(8):656-64.
- Framework for pharmacy services quality improvement—a bridge to cross the quality chasm. 2004;10(1):60-78.
• Information technology to cross the quality chasm. 2002;8(5):401-02.
• Crossing the quality chasm—incremental change through clinical practice guidelines (CPGs). [editorial] 2002;8(3):400-01.
• Quality improvement opportunities in health care—making it easy to do it right. 2002;8(5):394-99.
• Relationship of clinical factors to the use of COX-2 selective NSAIDs within an arthritis population in a large HMO. 2002;8(4):252-58.
• Quality measures: looking in all the wrong places. 2001,7(2):88.
• The case for pharmacy report cards. 1999,5(3):176, 179-80, 182.
• Managing drug therapy decisions: pay me now or pay me later. 1998,4(3):242, 245.
• Managed care and the quest for quality measures. 1997,3(2):255, 258-89.
• Successful CQI-based programs in a group-model managed care setting. 1995,1(2):134, 137.

Collaboration—Pharmacists and Others

• Prevalence and types of disease management programs in community pharmacies in California. 2005;11(6):505-12.
• Pharmacy practice in the long-term care environment. 1997,3(2):189-94.

Collaboration—Pharmacy Education

• A unique partnership: the Arkansas College of Pharmacy and the Arkansas PRO. 2002;8(1):12, 14.
• Oregon State University partners with Medicaid and a managed care organization. 2001,7(3):183-86.
• The University of Colorado School of Pharmacy and the University of Colorado Health Plan forge a PBM partnership. 1998,4(5):478, 480.

Collaborative Practice and Pharmacists as Prescribers


Computerized Prescription Order Entry, Electronic Prescribing, and Health Information Technology

• Standardization is necessary in the methods to assess the value of electronic prescribing systems. [letter] 2005;11(7):594-95.
• Extent of electronic prescribing implementation as perceived by MCO pharmacy managers. 2002,8(1):41-47.

Crohn’s Disease


Database Analyses of Drug Utilization

(see also Research Methods)

• Claims data and drawing appropriate conclusions. 2002;8(2):152.

www.amcp.org Vol. 17, No. 1 January/February 2011 JMCP Journal of Managed Care Pharmacy 77

Relationship of glycemic control to total diabetes-related costs for managed care health plan members with type 2 diabetes. 2005;11(7):559-64.


Direct-to-Consumer Advertising (DTCA) (see also Drug Promotion and Advertising)

- United States, the last venue for direct-to-consumer advertising, props up the erectile dysfunction market. [editorial] 2005;11(2):176-78.
- Direct-to-patient advertising (DTPA) and direct-to-consumer advertising (DTCA) of prescription drugs. 2002;8(6):521.

Disease Pathology and Prevention


Dose Optimization—Dose Consolidation and Tablet Splitting

- Initial results of the use of prescription order change forms to achieve dose form optimization (consolidation and tablet splitting) of SSRI antidepressants in a state Medicaid program. 2006;12(6):449-56.
- Randomized controlled trial of a dose consolidation program. 2004;10(5):396-403.
- Dose optimization: an opportunity for pharmacy administrative services. 2002;8(2):81.

Drug Benefit Management—Benchmarks and Measures

- Other DACON observations—community pharmacists do not intentionally transmit incorrect claim information—but caution is warranted in days supply calculations. [letter] 2004;10(2):174-75.
- Searching for drug benefit benchmarks—cost per day of therapy. 2002;8(1):54-55.

Drug Benefit Management—Benefit Design

- Making the world safe for evidence-based policy: let’s slay the biases in research on value-based insurance design. [editorial] 2008;14(2):198-204.
- Relationship of glycemic control to total diabetes-related costs for managed care health plan members with type 2 diabetes. 2005;11(7):559-64.
Comparison of mail-order with community pharmacy in plan sponsor cost and member cost in two large pharmacy benefit plans. 2007;13(2):122-34.

Relationship of the use and costs of physician office visits and prescription drugs to travel distance and increases in member cost share. 2006;12(8):665-76.


Cost reduction strategies used by elderly patients with chronic obstructive pulmonary disease to cope with a generic-only pharmacy benefit. 2006;12(5):377-82.


A 30-month evaluation of the effects on cost and utilization of proton pump inhibitors from adding omeprazole OTC to drug benefit coverage in a state employee health plan. 2006;12(1):25-32.

The role of pharmaceuticals in reducing cardiometabolic risk: rethinking pharmacy benefit design to reduce the burden on the health care system. [supplement] 2006;12(1):S1-S16.


Effects on the cost and utilization of proton pump inhibitors from adding over-the-counter omeprazole to drug benefit coverage in a state employee health plan. 2004;10(5):449-55.

Does member cost-sharing pose a threat to desirable patient outcomes? 2004;10(3):256.


Benefit maximums versus drug benefit needs for Medicare beneficiaries. 2002;8(5):402-03.

Prescription use behavior among Medicare beneficiaries with capped prescription benefits. 2002;8(5):360-64.


Weight uniformity of split tablets required by a Veterans Affairs policy. 2003;9(5):401-07.


Drug Benefit Management—Employee Benefits and Coverage


Successful disease management programs for health and welfare fund union groups. 1998;4(3):269-70, 272.

Drug Benefit Management—Generic Dispensing Ratio

- Description of the outcomes of prior authorization of palivizumab for prevention of respiratory syncytial virus infection in a managed care organization. 2010,16(1):15-22.
- Analysis of a prescription drug prior authorization program in a Medicaid health maintenance organization. 2003;9(1):36-44.
- Evaluation of a monthly coverage maximum (drug specific quantity limit) on the 5-HT1 agonists (triptans) and dihydroergotamine nasal spray. 2003,9(4):335-45.
- Description of the outcomes of prior authorization of palivizumab for prevention of respiratory syncytial virus infection in a managed care organization. 2010,16(1):15-22.
- Evaluation of health plan member use of an online prescription drug price comparison tool. 2010,16(9):680-92.
- Drugs, PPOs, tiered cost-share for beneficiaries, and consumer preferences. 2002,8(3):177.
- Patient satisfaction with and knowledge of their prescription drug coverage. 2001,7(1):34-42.

Drug Benefit Management—Patient Satisfaction, Benefit Knowledge, and Consumer Behavior

- Pharmacists and physician satisfaction and rates of switching to preferred medications associated with an instant prior authorization program for proton pump inhibitors in the North Carolina Medicaid program. 2010,16(4):250-63.

Drug Benefit Management—Step Therapy, and Prior Authorization (PA)

- Pharmacists and physician satisfaction and rates of switching to preferred medications associated with an instant prior authorization program for proton pump inhibitors in the North Carolina Medicaid program. 2010,16(4):250-63.
Drug Utilization Review (DUR) or Drug Utilization Management—Appropriate Drug Use

- Frequency of simvastatin prescriptions with potentially interacting medications in a Veterans Affairs health care system. 2004,10(3):239-43.
- Gabapentin may be appropriate for off-label uses. [editorial] 2003,9(6):569-70.
- Examination of the evidence for off-label use of gabapentin. 2003,9(6):559-68.

Dyslipidemia

- LDL-C goal attainment among patients newly diagnosed with coronary heart disease or diabetes in a commercial HMO. 2007,13(8):652-63.
- Results of retrospective chart review to determine improvement in lipid goal attainment in patients treated by high-volume prescribers of lipid-modifying drugs. 2006,12(9):745-51.
Clinical and economic outcomes of conversion of simvastatin to lovastatin in a group-model health maintenance organization. 2005;11(8):681-86.

Fish oil for heart disease—happy to be in second place. [editorial] 2005;11(7):584-85.

Similar medication compliance and control of dyslipidemia with simvastatin or atorvastatin in a staff-model HMO medical clinic. 2005;11(6):499-504.


Quantifying the effect of applying the NCEP ATP III criteria in a managed care population treated with statin therapy. 2004;10(3):244-50.


Effective cholesterol management with fewer dollars. 2002;8(6):519.


Ethics


Formulary Management—Methods and Effects—Pharmacoeconomics

The AMCP Format for Formulary Submissions, version 3.0 [supplement] 2010;16(1-3):S1-S32.


It’s only a pharmacoeconomic model—believe it or not. [editorial] 2008;14(1):83-87.


Opinions regarding the Academy of Managed Care Pharmacy dossier submission guidelines: results of a small survey of managed care organizations and pharmaceutical manufacturers. 2007;13(4):360-71.


Industry’s perception of presenting pharmacoeconomic models to managed care organizations. 2003;9(2):159-67.


Meta-analysis of oral triptan therapy for migraine: number needed to treat and relative cost to achieve relief within 2 hours. 2003;9(1):45-52.

• Exploring the methodological challenges of investigating comparison groups with different underlying characteristics: a case study. 2002;8(5):353-59.
• AMCP guidance for submission of clinical and economic evaluation data to support formulary listing in U.S. health plans and pharmacy benefits management organizations. 2001;7(4):272-82.
• The pros and cons of formularies. 2000;6(3):203-07.
• The role of pharmacoeconomic information in the formulary decision-making process. 2000;6(2):108, 113-14, 117-18, 121.
• Outcome analysis of a formulary transition from nifedipine to felodipine at a Veterans Affairs Medical Center. 1999;5(5):425-28.
• Formulary management by an on-site school of pharmacy faculty member in a Medicaid managed care organization. 1998;4(4):407-10.
• DOD’s Pharmacoeconomic Center: translating research into good patient care practices. 1997;3(6):662-64, 666.
• Drug formularies: real opportunities to improve MCO efficiency. 1997;3(3):254, 375-76.
• Using outcomes as a tool to evaluate formulary selection decisions: hypercholesterolemia as a case example. 1996;2(4):396-404.

Formulary Management—P&T Committees

Gout
• Disease-related and all-cause health care costs of elderly patients with gout. 2008;14(2):164-75.

Health Care Delivery and Health Promotion
• Shape It Up – A school-based education program to promote healthy eating and exercise developed by a health plan in collaboration with a college of pharmacy. 2009;15(5):403-13.
• A review of the use of CAM therapy and the sources of accurate and reliable information. 2005;11(8):695-703.
• Development of a complementary and alternative medicine (CAM) pharmacy and therapeutics (P&T) subcommittee and CAM guide for providers. 2005;11(3):252-58.
• International markets offer new opportunities for MCOs and PBMs. 1997;3(4):403-04, 409-10.
• Integration takes managed care in different directions: horizontal, vertical, and beyond. 1997;3(3):260, 263-64.
• Alternative medicine in managed care pharmacy. 1997;3(1):77-80, 83-84.
• Indian Health Service: paving the way for pharmaceutical care. 1997;3(1):36, 41-43.
• While health care evolves, antitrust law endures. 1996;2(6):679-86.

Health Care Spending and Health Economics
• Medical costs and resource utilization for hemophilia patients with and without HIV or HCV infection. 2007;13(9):790-98.
• Is there no prescription to decrease health care outlays in the face of an aging population? 2000;6(6):450-51.
• Health economics II: some unique aspects of health economics. 2000;6(2):173-78.

Health Insurance and Health Care Finance
• Direct contracting: the next purchaser strategy. 1996;2(1):11-12, 14, 16.

Heartburn and Acid-Related Disorders
• Employers need to have a wider horizon than drug costs alone when considering the implementation of health care intervention programs. [letter and author response] 2006;12(7):581-83.
• PPIs are therapeutically interchangeable and ideal for a managed care intervention such as therapeutic MAC. [editorial] 2006;12(7):578-80.


Hypertension and Cardiovascular Disease


Health care resources and costs for treating peripheral artery disease in a managed care population: results from analysis of administrative claims data. 2005;11(9):727-34.


Antihypertensive drug effects on renal function and myocardial infarction and implications of the ALLHAT study results. 2003;9(1):93-95.

Impact of the ALLHAT study results on managed care. 2003;9(1):84-86.


Infectious Disease


Fluoroquinolone-use evaluation for acute cystitis. 1996;2(5):564-68.

Institutional Managed Care

Managed pharmaceutical care within a criminal justice system. 2001;7(3):182.

Internet Pharmacy

Concern about foreign-source pharmacy Internet providers. 2001;7(3):335-36.

The Internet and PBMs: new business model or business as usual? 2001;7(3):182.


Fluoroquinolone-use evaluation for acute cystitis. 1996;2(5):564-68.

Irritable Bowel Syndrome


Lifestyle Drugs


Managed Care Pharmacy Practice
- Effect of 6 managed care pharmacy tools: a review of the literature. [supplement] 2010;16(6–a):S1-S20
- Quality articles require peer reviewers—as well as authors. [letter] 2005;11(2):186
- John Ogden talks about managed care in the Veterans Administration. 2002;8(2):91-93.
- The changing face of managed care pharmacy and the role of PBMs. 1997;3(5):494, 497-98.

Managed Health Care

Medicaid; and Medication Therapy Management (MTM)

Medicare; and Medication Therapy Management Programs (MTM) (see also Clinical Pharmacy Interventions – Clinical, Service and Cost Outcomes)
- Sound medication therapy management programs, version 2.0 – with validation study. [supplement] 2008;14(1, S-b):S1-S44.
- Unprecedented opportunities for managed care and community pharmacy to work together. 2007;13(5):426-28.
- Characteristics of older adults who meet the annual prescription drug expenditure threshold for Medicare medication therapy management programs. 2007;13(2):142-54.
- Prescription coverage options for Medicare beneficiaries. 1999;5(3):250-34.

Migraine Syndrome
• Assessment of clinical, service, and cost outcomes of a conversion program of sumatriptan to rizatriptan ODT in primary care patients with migraine headaches. 2006;12(3):246-53.
• Which is more elusive, the pot of gold at the end of a rainbow or determining the most cost-effective triptan? [editorial] 2005;11(6):S13-15.
• Triptans for migraine therapy: a comparison based on number needed to treat and doses needed to treat. 2005;11(5):394-402.
• Costs and utilization of triptan users who receive drug prophylaxis for migraine versus triptan users who do not receive drug prophylaxis. 2005;11(12):137-44.
• Which triptan?—Opportunity for same or better outcomes at lower cost. [editorial] 2004;10(3):266.
• Meta-analysis of oral triptan therapy for migraine: number needed to treat and relative cost to achieve relief within 2 hours. 2003;9(1):45-52.

**Multiple Sclerosis**

• Price increases and new drugs drive increased expenditures for multiple sclerosis. 2010;16(9):713-17.
• All-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the United States. 2010;16(9):703-12.
• Gender differences in self-reported symptom awareness and perceived ability to manage therapy with disease-modifying medication among commercially insured multiple sclerosis patients. 2010;16(3):206-16.
• Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database. 2007;13(1):44-52.

**Obesity**

• The role of pharmaceuticals in reducing cardiometabolic risk: rethinking pharmacy benefit design to reduce the burden on the health care system. [supplement] 2006;12(3):S1-S16.
• “U Can’t Touch This” with pharmacotherapy alone for weight loss or smoking cessation. [editorial] 2005;11(6):S16-20.
• Cost-effectiveness of sibutramine in the LOSE Weight Study: evaluating the role of pharmacologic weight-loss therapy within a weight management program. 2005;11(6):458-68.
• A cost-effective analysis of appetite suppressants for obesity treatment in a managed care organization. 1998;4(3):293-300.

**Osteoporosis**

• 3-year results of a member and physician intervention to reduce risk associated with glucocorticoid-induced osteoporosis in a health plan. 2008;14(3):281-90.
• Comparison of risedronate to alendronate and calcitonin for early reduction of nonvertebral fracture risk: results from a managed care administrative claims database. 2004;10(2):142-51.
• The cost of treating osteoporosis in a managed health care organization. 2003;9(2):142-49.

**Pain Management**

• Beyond narcotics for effective pain management. 2003;9(2):175-76.
• It’s a pain. 1999;5(6):558.
Parkinson's Disease, Seizure Disorders, and Epilepsy
- Step therapy is not appropriate for antiepileptic drugs. [letter] 2006;12(3):269-70.

Pharmaceutical Industry and Marketing
- Pharmaceutical patient assistance programs: don’t look a gift horse in the mouth or there’s no such thing as a free lunch. [commentary] 2007;13(7):611-13.
- Product-line extensions and pricing strategies of brand-name drugs facing patent expiration. 2005;11(9):746-54.

Pharmaceutical Pricing, Rebates and Pharmacy Reimbursement
- What is the price benchmark to replace average wholesale price (AWP)? 2010;16(7):492-501.

Pharmacogenomics
- Health care professionals’ perceptions of the role of pharmacogenomic data. 2002;8(4):278-84.

Pharmacy Education
- Pharmacy students’ views of managed care pharmacy and PBMs: should there be more exposure to managed care in the pharmacy curriculum? 2010;16(5):346-54.
- Managed care and the University of Texas College of Pharmacy. 2001;7(6):490.
- University of Michigan College of Pharmacy and managed care partner to enhance drug therapy. 2001,7(5):345-46.
- An inside look at the benefits of a student pharmacy and therapeutics (P&T) committee competition from the University of Illinois at Chicago. 2001;7(4):299-60.
- Managed care concepts prominently featured in innovative management programs at Duquesne University. 2001;7(2):94, 96.
- The University of Maryland’s Center on Drugs and Public Policy. 2000;6(2):184-85.
- Managed care pharmacy practice at the Texas Tech University Health Sciences Center School of Pharmacy. 1999,5(6):556-57.
- Description of a formal affiliation between a school of pharmacy and a managed care organization. 1999,5(5):433-37.
Assessment of eptifibatide dosing in renal impairment before
Including Academic Detailing

Physician Education Interventions


Managed care pharmacy at the St. Louis College of Pharmacy. 1996;2(2):39, 42.


Managed care pharmacy education at the University of Washington School of Pharmacy. 1996;2(3):319-20.

Managed care pharmacy education at MCP. 1996;2(1):53.

Physician Education Interventions
Including Academic Detailing

• Assessment of eptifibatide dosing in renal impairment before and after in-service education provided by pharmacists. 2007;13(7):988-906.
• Selection bias in physician education-intervention programs. 2002;8(2):82.
• Driving market share in an integrated health system without therapeutic interchange. 2001;7(4):283-86.

• UIC students mobilize first student chapter of AMCP. 1995;1(3):185-86.

Population Health—Interventions and Prevention of ADEs

• Suboptimal pneumococcal pneumonia vaccination rates among patients at risk in a managed care organization in Israel. 2006;12(3):152-56.

Privacy of Health Information

• The Health Insurance Portability and Accountability Act of 1996 (HIPAA) and the pharmacy benefit: implications for health plans, PBMs, and providers. 2003;9(1):66-71.
• Employer access to employee prescription records: dilemmas for pharmacists. 1997;3(5):504-05, 508.

Psoriasis


Quality Assurance


Research Methods and Statistical Analysis (see also Survey Methods)

• Peeking inside the statistical black box: how to analyze quantitative information and get it right the first time. [editorial] 2007;13(1):70-74.
• Conjoint analysis in pharmaceutical research. 2002;8(3):206-08.
• Researching managed care pharmacy using Internet searches. 2001;7(3):201-04, 213.
• Method is everything: evaluating results by study design. 1997;3(1):66-68, 71-72, 75-76.
• Epidemiological techniques. 1997;3(1):30-32, 35.
• Interface between pharmacoepidemiology and pharmacoconomics in managed care pharmacy. 1996;2(3):282-289.
• Outcomes research, pharmacoconomics, and the pharmaceutical industry. 1996;2(1):48-52.

Safety—Health Care Worker

Safety—Patient Care (see Drug Utilization Review [DUR])

Specialty Pharmacy
• Specialty pharmacy cost management strategies of private health care payers. 2006;12(9):736-744.
• The emergence of specialty pharmacy. 2000;6(4):280-284.

Survey Methods (see also Research Methods)
• Constructing mail survey questionnaires to maximize the rates of return and assure the validity and reliability of responses. 2002;8(3):225-231.
• Implementing mail survey questionnaires. 2002;8(2):157-161.

Technology—Automation, Education and Information
• Use of technology throughout the curriculum. 2002;8(2):86.
• Automation aids prescription processing—but professional judgment remains indispensable. 1995;1(2):90, 93-95.

Therapeutic Interchange—Therapeutic Selection (see also Formulary Management, and Drug Benefit Design)
• Utilization of pharmacy claims data to evaluate therapeutic interchange programs. 1999;5(4):331-344.

Thrombosis, DVT, and VTE
• Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. 2007;13(6):475-486.
• Effect of a clinical pharmacy education program on improvement in the quantity and quality of venous thromboembolism prophylaxis for medically ill patients. 2005;11(10):755-758.
• In search of safe and effective oral anticoagulation. [editorial] 2005;11(8):704-708.
• Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism event during hospitalization. 2005;11(8):683-732.

Ulcerative Colitis
• Administrative claims analysis of all-cause annual costs of care and resource utilization by age category for ulcerative colitis patients. 2008;14(4):352-362.
• The challenge of compliance and persistence: focus on ulcerative colitis.[supplement] 2008;14(1, S-a):S1-S16.
• Mild-to-moderate ulcerative colitis: your role in patient compliance and health care costs. [supplement] 2007;13(7, S-a):S1-S16.

Value of Pharmacotherapy
• RxHealthValue offers three recommendations and cost research. 2001;1(7):17-20.

Women’s Health
• Actuarial analysis of private payer administrative claims data for women with endometriosis. 2007;13(3):262-272.